Medical Care
Global Respiratory Antiviral Treatment Market Research Report 2025
- Jul 08, 25
- ID: 347388
- Pages: 79
- Figures: 73
- Views: 1
The global market for Respiratory Antiviral Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Respiratory Antiviral Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Antiviral Treatment.
The Respiratory Antiviral Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Respiratory Antiviral Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Respiratory Antiviral Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
F. Hoffmann-La Roche Ltd.
Novartis AG
Takeda Pharmaceutical Company Limited
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
GlaxoSmithKline plc
Mylan Inc.
Merck & Co., Inc.
AstraZeneca plc.
Segment by Type
Influenza
Bronchiolitis
Pneumonia
Upper Respiratory Tract Infections (URTIs)
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Antiviral Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Respiratory Antiviral Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Antiviral Treatment.
The Respiratory Antiviral Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Respiratory Antiviral Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Respiratory Antiviral Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
F. Hoffmann-La Roche Ltd.
Novartis AG
Takeda Pharmaceutical Company Limited
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
GlaxoSmithKline plc
Mylan Inc.
Merck & Co., Inc.
AstraZeneca plc.
Segment by Type
Influenza
Bronchiolitis
Pneumonia
Upper Respiratory Tract Infections (URTIs)
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Antiviral Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Respiratory Antiviral Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Influenza
1.2.3 Bronchiolitis
1.2.4 Pneumonia
1.2.5 Upper Respiratory Tract Infections (URTIs)
1.2.6 Others
1.3 Market by Application
1.3.1 Global Respiratory Antiviral Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Respiratory Antiviral Treatment Market Perspective (2020-2031)
2.2 Global Respiratory Antiviral Treatment Growth Trends by Region
2.2.1 Global Respiratory Antiviral Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Respiratory Antiviral Treatment Historic Market Size by Region (2020-2025)
2.2.3 Respiratory Antiviral Treatment Forecasted Market Size by Region (2026-2031)
2.3 Respiratory Antiviral Treatment Market Dynamics
2.3.1 Respiratory Antiviral Treatment Industry Trends
2.3.2 Respiratory Antiviral Treatment Market Drivers
2.3.3 Respiratory Antiviral Treatment Market Challenges
2.3.4 Respiratory Antiviral Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Respiratory Antiviral Treatment Players by Revenue
3.1.1 Global Top Respiratory Antiviral Treatment Players by Revenue (2020-2025)
3.1.2 Global Respiratory Antiviral Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Respiratory Antiviral Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Respiratory Antiviral Treatment Revenue
3.4 Global Respiratory Antiviral Treatment Market Concentration Ratio
3.4.1 Global Respiratory Antiviral Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Respiratory Antiviral Treatment Revenue in 2024
3.5 Global Key Players of Respiratory Antiviral Treatment Head office and Area Served
3.6 Global Key Players of Respiratory Antiviral Treatment, Product and Application
3.7 Global Key Players of Respiratory Antiviral Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Respiratory Antiviral Treatment Breakdown Data by Type
4.1 Global Respiratory Antiviral Treatment Historic Market Size by Type (2020-2025)
4.2 Global Respiratory Antiviral Treatment Forecasted Market Size by Type (2026-2031)
5 Respiratory Antiviral Treatment Breakdown Data by Application
5.1 Global Respiratory Antiviral Treatment Historic Market Size by Application (2020-2025)
5.2 Global Respiratory Antiviral Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Respiratory Antiviral Treatment Market Size (2020-2031)
6.2 North America Respiratory Antiviral Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Respiratory Antiviral Treatment Market Size by Country (2020-2025)
6.4 North America Respiratory Antiviral Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Respiratory Antiviral Treatment Market Size (2020-2031)
7.2 Europe Respiratory Antiviral Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Respiratory Antiviral Treatment Market Size by Country (2020-2025)
7.4 Europe Respiratory Antiviral Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Respiratory Antiviral Treatment Market Size (2020-2031)
8.2 Asia-Pacific Respiratory Antiviral Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Respiratory Antiviral Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Respiratory Antiviral Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Respiratory Antiviral Treatment Market Size (2020-2031)
9.2 Latin America Respiratory Antiviral Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Respiratory Antiviral Treatment Market Size by Country (2020-2025)
9.4 Latin America Respiratory Antiviral Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Respiratory Antiviral Treatment Market Size (2020-2031)
10.2 Middle East & Africa Respiratory Antiviral Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Respiratory Antiviral Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Respiratory Antiviral Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 F. Hoffmann-La Roche Ltd.
11.1.1 F. Hoffmann-La Roche Ltd. Company Details
11.1.2 F. Hoffmann-La Roche Ltd. Business Overview
11.1.3 F. Hoffmann-La Roche Ltd. Respiratory Antiviral Treatment Introduction
11.1.4 F. Hoffmann-La Roche Ltd. Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.1.5 F. Hoffmann-La Roche Ltd. Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Details
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Respiratory Antiviral Treatment Introduction
11.2.4 Novartis AG Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.2.5 Novartis AG Recent Development
11.3 Takeda Pharmaceutical Company Limited
11.3.1 Takeda Pharmaceutical Company Limited Company Details
11.3.2 Takeda Pharmaceutical Company Limited Business Overview
11.3.3 Takeda Pharmaceutical Company Limited Respiratory Antiviral Treatment Introduction
11.3.4 Takeda Pharmaceutical Company Limited Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.3.5 Takeda Pharmaceutical Company Limited Recent Development
11.4 Pfizer, Inc.
11.4.1 Pfizer, Inc. Company Details
11.4.2 Pfizer, Inc. Business Overview
11.4.3 Pfizer, Inc. Respiratory Antiviral Treatment Introduction
11.4.4 Pfizer, Inc. Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.4.5 Pfizer, Inc. Recent Development
11.5 Teva Pharmaceutical Industries Ltd.
11.5.1 Teva Pharmaceutical Industries Ltd. Company Details
11.5.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.5.3 Teva Pharmaceutical Industries Ltd. Respiratory Antiviral Treatment Introduction
11.5.4 Teva Pharmaceutical Industries Ltd. Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.5.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.6 Sun Pharmaceutical Industries Ltd.
11.6.1 Sun Pharmaceutical Industries Ltd. Company Details
11.6.2 Sun Pharmaceutical Industries Ltd. Business Overview
11.6.3 Sun Pharmaceutical Industries Ltd. Respiratory Antiviral Treatment Introduction
11.6.4 Sun Pharmaceutical Industries Ltd. Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.6.5 Sun Pharmaceutical Industries Ltd. Recent Development
11.7 GlaxoSmithKline plc
11.7.1 GlaxoSmithKline plc Company Details
11.7.2 GlaxoSmithKline plc Business Overview
11.7.3 GlaxoSmithKline plc Respiratory Antiviral Treatment Introduction
11.7.4 GlaxoSmithKline plc Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.7.5 GlaxoSmithKline plc Recent Development
11.8 Mylan Inc.
11.8.1 Mylan Inc. Company Details
11.8.2 Mylan Inc. Business Overview
11.8.3 Mylan Inc. Respiratory Antiviral Treatment Introduction
11.8.4 Mylan Inc. Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.8.5 Mylan Inc. Recent Development
11.9 Merck & Co., Inc.
11.9.1 Merck & Co., Inc. Company Details
11.9.2 Merck & Co., Inc. Business Overview
11.9.3 Merck & Co., Inc. Respiratory Antiviral Treatment Introduction
11.9.4 Merck & Co., Inc. Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.9.5 Merck & Co., Inc. Recent Development
11.10 AstraZeneca plc.
11.10.1 AstraZeneca plc. Company Details
11.10.2 AstraZeneca plc. Business Overview
11.10.3 AstraZeneca plc. Respiratory Antiviral Treatment Introduction
11.10.4 AstraZeneca plc. Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.10.5 AstraZeneca plc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Respiratory Antiviral Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Influenza
1.2.3 Bronchiolitis
1.2.4 Pneumonia
1.2.5 Upper Respiratory Tract Infections (URTIs)
1.2.6 Others
1.3 Market by Application
1.3.1 Global Respiratory Antiviral Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Respiratory Antiviral Treatment Market Perspective (2020-2031)
2.2 Global Respiratory Antiviral Treatment Growth Trends by Region
2.2.1 Global Respiratory Antiviral Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Respiratory Antiviral Treatment Historic Market Size by Region (2020-2025)
2.2.3 Respiratory Antiviral Treatment Forecasted Market Size by Region (2026-2031)
2.3 Respiratory Antiviral Treatment Market Dynamics
2.3.1 Respiratory Antiviral Treatment Industry Trends
2.3.2 Respiratory Antiviral Treatment Market Drivers
2.3.3 Respiratory Antiviral Treatment Market Challenges
2.3.4 Respiratory Antiviral Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Respiratory Antiviral Treatment Players by Revenue
3.1.1 Global Top Respiratory Antiviral Treatment Players by Revenue (2020-2025)
3.1.2 Global Respiratory Antiviral Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Respiratory Antiviral Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Respiratory Antiviral Treatment Revenue
3.4 Global Respiratory Antiviral Treatment Market Concentration Ratio
3.4.1 Global Respiratory Antiviral Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Respiratory Antiviral Treatment Revenue in 2024
3.5 Global Key Players of Respiratory Antiviral Treatment Head office and Area Served
3.6 Global Key Players of Respiratory Antiviral Treatment, Product and Application
3.7 Global Key Players of Respiratory Antiviral Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Respiratory Antiviral Treatment Breakdown Data by Type
4.1 Global Respiratory Antiviral Treatment Historic Market Size by Type (2020-2025)
4.2 Global Respiratory Antiviral Treatment Forecasted Market Size by Type (2026-2031)
5 Respiratory Antiviral Treatment Breakdown Data by Application
5.1 Global Respiratory Antiviral Treatment Historic Market Size by Application (2020-2025)
5.2 Global Respiratory Antiviral Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Respiratory Antiviral Treatment Market Size (2020-2031)
6.2 North America Respiratory Antiviral Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Respiratory Antiviral Treatment Market Size by Country (2020-2025)
6.4 North America Respiratory Antiviral Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Respiratory Antiviral Treatment Market Size (2020-2031)
7.2 Europe Respiratory Antiviral Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Respiratory Antiviral Treatment Market Size by Country (2020-2025)
7.4 Europe Respiratory Antiviral Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Respiratory Antiviral Treatment Market Size (2020-2031)
8.2 Asia-Pacific Respiratory Antiviral Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Respiratory Antiviral Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Respiratory Antiviral Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Respiratory Antiviral Treatment Market Size (2020-2031)
9.2 Latin America Respiratory Antiviral Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Respiratory Antiviral Treatment Market Size by Country (2020-2025)
9.4 Latin America Respiratory Antiviral Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Respiratory Antiviral Treatment Market Size (2020-2031)
10.2 Middle East & Africa Respiratory Antiviral Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Respiratory Antiviral Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Respiratory Antiviral Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 F. Hoffmann-La Roche Ltd.
11.1.1 F. Hoffmann-La Roche Ltd. Company Details
11.1.2 F. Hoffmann-La Roche Ltd. Business Overview
11.1.3 F. Hoffmann-La Roche Ltd. Respiratory Antiviral Treatment Introduction
11.1.4 F. Hoffmann-La Roche Ltd. Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.1.5 F. Hoffmann-La Roche Ltd. Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Details
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Respiratory Antiviral Treatment Introduction
11.2.4 Novartis AG Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.2.5 Novartis AG Recent Development
11.3 Takeda Pharmaceutical Company Limited
11.3.1 Takeda Pharmaceutical Company Limited Company Details
11.3.2 Takeda Pharmaceutical Company Limited Business Overview
11.3.3 Takeda Pharmaceutical Company Limited Respiratory Antiviral Treatment Introduction
11.3.4 Takeda Pharmaceutical Company Limited Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.3.5 Takeda Pharmaceutical Company Limited Recent Development
11.4 Pfizer, Inc.
11.4.1 Pfizer, Inc. Company Details
11.4.2 Pfizer, Inc. Business Overview
11.4.3 Pfizer, Inc. Respiratory Antiviral Treatment Introduction
11.4.4 Pfizer, Inc. Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.4.5 Pfizer, Inc. Recent Development
11.5 Teva Pharmaceutical Industries Ltd.
11.5.1 Teva Pharmaceutical Industries Ltd. Company Details
11.5.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.5.3 Teva Pharmaceutical Industries Ltd. Respiratory Antiviral Treatment Introduction
11.5.4 Teva Pharmaceutical Industries Ltd. Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.5.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.6 Sun Pharmaceutical Industries Ltd.
11.6.1 Sun Pharmaceutical Industries Ltd. Company Details
11.6.2 Sun Pharmaceutical Industries Ltd. Business Overview
11.6.3 Sun Pharmaceutical Industries Ltd. Respiratory Antiviral Treatment Introduction
11.6.4 Sun Pharmaceutical Industries Ltd. Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.6.5 Sun Pharmaceutical Industries Ltd. Recent Development
11.7 GlaxoSmithKline plc
11.7.1 GlaxoSmithKline plc Company Details
11.7.2 GlaxoSmithKline plc Business Overview
11.7.3 GlaxoSmithKline plc Respiratory Antiviral Treatment Introduction
11.7.4 GlaxoSmithKline plc Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.7.5 GlaxoSmithKline plc Recent Development
11.8 Mylan Inc.
11.8.1 Mylan Inc. Company Details
11.8.2 Mylan Inc. Business Overview
11.8.3 Mylan Inc. Respiratory Antiviral Treatment Introduction
11.8.4 Mylan Inc. Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.8.5 Mylan Inc. Recent Development
11.9 Merck & Co., Inc.
11.9.1 Merck & Co., Inc. Company Details
11.9.2 Merck & Co., Inc. Business Overview
11.9.3 Merck & Co., Inc. Respiratory Antiviral Treatment Introduction
11.9.4 Merck & Co., Inc. Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.9.5 Merck & Co., Inc. Recent Development
11.10 AstraZeneca plc.
11.10.1 AstraZeneca plc. Company Details
11.10.2 AstraZeneca plc. Business Overview
11.10.3 AstraZeneca plc. Respiratory Antiviral Treatment Introduction
11.10.4 AstraZeneca plc. Revenue in Respiratory Antiviral Treatment Business (2020-2025)
11.10.5 AstraZeneca plc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Respiratory Antiviral Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Influenza
Table 3. Key Players of Bronchiolitis
Table 4. Key Players of Pneumonia
Table 5. Key Players of Upper Respiratory Tract Infections (URTIs)
Table 6. Key Players of Others
Table 7. Global Respiratory Antiviral Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Respiratory Antiviral Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Respiratory Antiviral Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Respiratory Antiviral Treatment Market Share by Region (2020-2025)
Table 11. Global Respiratory Antiviral Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Respiratory Antiviral Treatment Market Share by Region (2026-2031)
Table 13. Respiratory Antiviral Treatment Market Trends
Table 14. Respiratory Antiviral Treatment Market Drivers
Table 15. Respiratory Antiviral Treatment Market Challenges
Table 16. Respiratory Antiviral Treatment Market Restraints
Table 17. Global Respiratory Antiviral Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Respiratory Antiviral Treatment Market Share by Players (2020-2025)
Table 19. Global Top Respiratory Antiviral Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Antiviral Treatment as of 2024)
Table 20. Ranking of Global Top Respiratory Antiviral Treatment Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Respiratory Antiviral Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Respiratory Antiviral Treatment, Headquarters and Area Served
Table 23. Global Key Players of Respiratory Antiviral Treatment, Product and Application
Table 24. Global Key Players of Respiratory Antiviral Treatment, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Respiratory Antiviral Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Respiratory Antiviral Treatment Revenue Market Share by Type (2020-2025)
Table 28. Global Respiratory Antiviral Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Respiratory Antiviral Treatment Revenue Market Share by Type (2026-2031)
Table 30. Global Respiratory Antiviral Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Respiratory Antiviral Treatment Revenue Market Share by Application (2020-2025)
Table 32. Global Respiratory Antiviral Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Respiratory Antiviral Treatment Revenue Market Share by Application (2026-2031)
Table 34. North America Respiratory Antiviral Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Respiratory Antiviral Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Respiratory Antiviral Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Respiratory Antiviral Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Respiratory Antiviral Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Respiratory Antiviral Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Respiratory Antiviral Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Respiratory Antiviral Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Respiratory Antiviral Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Respiratory Antiviral Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Respiratory Antiviral Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Respiratory Antiviral Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Respiratory Antiviral Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Respiratory Antiviral Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Respiratory Antiviral Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 49. F. Hoffmann-La Roche Ltd. Company Details
Table 50. F. Hoffmann-La Roche Ltd. Business Overview
Table 51. F. Hoffmann-La Roche Ltd. Respiratory Antiviral Treatment Product
Table 52. F. Hoffmann-La Roche Ltd. Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 53. F. Hoffmann-La Roche Ltd. Recent Development
Table 54. Novartis AG Company Details
Table 55. Novartis AG Business Overview
Table 56. Novartis AG Respiratory Antiviral Treatment Product
Table 57. Novartis AG Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 58. Novartis AG Recent Development
Table 59. Takeda Pharmaceutical Company Limited Company Details
Table 60. Takeda Pharmaceutical Company Limited Business Overview
Table 61. Takeda Pharmaceutical Company Limited Respiratory Antiviral Treatment Product
Table 62. Takeda Pharmaceutical Company Limited Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 63. Takeda Pharmaceutical Company Limited Recent Development
Table 64. Pfizer, Inc. Company Details
Table 65. Pfizer, Inc. Business Overview
Table 66. Pfizer, Inc. Respiratory Antiviral Treatment Product
Table 67. Pfizer, Inc. Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 68. Pfizer, Inc. Recent Development
Table 69. Teva Pharmaceutical Industries Ltd. Company Details
Table 70. Teva Pharmaceutical Industries Ltd. Business Overview
Table 71. Teva Pharmaceutical Industries Ltd. Respiratory Antiviral Treatment Product
Table 72. Teva Pharmaceutical Industries Ltd. Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 73. Teva Pharmaceutical Industries Ltd. Recent Development
Table 74. Sun Pharmaceutical Industries Ltd. Company Details
Table 75. Sun Pharmaceutical Industries Ltd. Business Overview
Table 76. Sun Pharmaceutical Industries Ltd. Respiratory Antiviral Treatment Product
Table 77. Sun Pharmaceutical Industries Ltd. Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 78. Sun Pharmaceutical Industries Ltd. Recent Development
Table 79. GlaxoSmithKline plc Company Details
Table 80. GlaxoSmithKline plc Business Overview
Table 81. GlaxoSmithKline plc Respiratory Antiviral Treatment Product
Table 82. GlaxoSmithKline plc Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 83. GlaxoSmithKline plc Recent Development
Table 84. Mylan Inc. Company Details
Table 85. Mylan Inc. Business Overview
Table 86. Mylan Inc. Respiratory Antiviral Treatment Product
Table 87. Mylan Inc. Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 88. Mylan Inc. Recent Development
Table 89. Merck & Co., Inc. Company Details
Table 90. Merck & Co., Inc. Business Overview
Table 91. Merck & Co., Inc. Respiratory Antiviral Treatment Product
Table 92. Merck & Co., Inc. Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 93. Merck & Co., Inc. Recent Development
Table 94. AstraZeneca plc. Company Details
Table 95. AstraZeneca plc. Business Overview
Table 96. AstraZeneca plc. Respiratory Antiviral Treatment Product
Table 97. AstraZeneca plc. Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 98. AstraZeneca plc. Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
Table 102. Authors List of This Report
List of Figures
Figure 1. Respiratory Antiviral Treatment Picture
Figure 2. Global Respiratory Antiviral Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Respiratory Antiviral Treatment Market Share by Type: 2024 VS 2031
Figure 4. Influenza Features
Figure 5. Bronchiolitis Features
Figure 6. Pneumonia Features
Figure 7. Upper Respiratory Tract Infections (URTIs) Features
Figure 8. Others Features
Figure 9. Global Respiratory Antiviral Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Respiratory Antiviral Treatment Market Share by Application: 2024 VS 2031
Figure 11. Hospital Pharmacies Case Studies
Figure 12. Retail Pharmacies Case Studies
Figure 13. Online Pharmacies Case Studies
Figure 14. Respiratory Antiviral Treatment Report Years Considered
Figure 15. Global Respiratory Antiviral Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Respiratory Antiviral Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Respiratory Antiviral Treatment Market Share by Region: 2024 VS 2031
Figure 18. Global Respiratory Antiviral Treatment Market Share by Players in 2024
Figure 19. Global Top Respiratory Antiviral Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Antiviral Treatment as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Respiratory Antiviral Treatment Revenue in 2024
Figure 21. North America Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Respiratory Antiviral Treatment Market Share by Country (2020-2031)
Figure 23. United States Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Respiratory Antiviral Treatment Market Share by Country (2020-2031)
Figure 27. Germany Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Respiratory Antiviral Treatment Market Share by Region (2020-2031)
Figure 35. China Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Respiratory Antiviral Treatment Market Share by Country (2020-2031)
Figure 43. Mexico Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Respiratory Antiviral Treatment Market Share by Country (2020-2031)
Figure 47. Turkey Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 51. Novartis AG Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 52. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 53. Pfizer, Inc. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 54. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 55. Sun Pharmaceutical Industries Ltd. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 56. GlaxoSmithKline plc Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 57. Mylan Inc. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 58. Merck & Co., Inc. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 59. AstraZeneca plc. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Table 1. Global Respiratory Antiviral Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Influenza
Table 3. Key Players of Bronchiolitis
Table 4. Key Players of Pneumonia
Table 5. Key Players of Upper Respiratory Tract Infections (URTIs)
Table 6. Key Players of Others
Table 7. Global Respiratory Antiviral Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Respiratory Antiviral Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Respiratory Antiviral Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Respiratory Antiviral Treatment Market Share by Region (2020-2025)
Table 11. Global Respiratory Antiviral Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Respiratory Antiviral Treatment Market Share by Region (2026-2031)
Table 13. Respiratory Antiviral Treatment Market Trends
Table 14. Respiratory Antiviral Treatment Market Drivers
Table 15. Respiratory Antiviral Treatment Market Challenges
Table 16. Respiratory Antiviral Treatment Market Restraints
Table 17. Global Respiratory Antiviral Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Respiratory Antiviral Treatment Market Share by Players (2020-2025)
Table 19. Global Top Respiratory Antiviral Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Antiviral Treatment as of 2024)
Table 20. Ranking of Global Top Respiratory Antiviral Treatment Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Respiratory Antiviral Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Respiratory Antiviral Treatment, Headquarters and Area Served
Table 23. Global Key Players of Respiratory Antiviral Treatment, Product and Application
Table 24. Global Key Players of Respiratory Antiviral Treatment, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Respiratory Antiviral Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Respiratory Antiviral Treatment Revenue Market Share by Type (2020-2025)
Table 28. Global Respiratory Antiviral Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Respiratory Antiviral Treatment Revenue Market Share by Type (2026-2031)
Table 30. Global Respiratory Antiviral Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Respiratory Antiviral Treatment Revenue Market Share by Application (2020-2025)
Table 32. Global Respiratory Antiviral Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Respiratory Antiviral Treatment Revenue Market Share by Application (2026-2031)
Table 34. North America Respiratory Antiviral Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Respiratory Antiviral Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Respiratory Antiviral Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Respiratory Antiviral Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Respiratory Antiviral Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Respiratory Antiviral Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Respiratory Antiviral Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Respiratory Antiviral Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Respiratory Antiviral Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Respiratory Antiviral Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Respiratory Antiviral Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Respiratory Antiviral Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Respiratory Antiviral Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Respiratory Antiviral Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Respiratory Antiviral Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 49. F. Hoffmann-La Roche Ltd. Company Details
Table 50. F. Hoffmann-La Roche Ltd. Business Overview
Table 51. F. Hoffmann-La Roche Ltd. Respiratory Antiviral Treatment Product
Table 52. F. Hoffmann-La Roche Ltd. Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 53. F. Hoffmann-La Roche Ltd. Recent Development
Table 54. Novartis AG Company Details
Table 55. Novartis AG Business Overview
Table 56. Novartis AG Respiratory Antiviral Treatment Product
Table 57. Novartis AG Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 58. Novartis AG Recent Development
Table 59. Takeda Pharmaceutical Company Limited Company Details
Table 60. Takeda Pharmaceutical Company Limited Business Overview
Table 61. Takeda Pharmaceutical Company Limited Respiratory Antiviral Treatment Product
Table 62. Takeda Pharmaceutical Company Limited Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 63. Takeda Pharmaceutical Company Limited Recent Development
Table 64. Pfizer, Inc. Company Details
Table 65. Pfizer, Inc. Business Overview
Table 66. Pfizer, Inc. Respiratory Antiviral Treatment Product
Table 67. Pfizer, Inc. Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 68. Pfizer, Inc. Recent Development
Table 69. Teva Pharmaceutical Industries Ltd. Company Details
Table 70. Teva Pharmaceutical Industries Ltd. Business Overview
Table 71. Teva Pharmaceutical Industries Ltd. Respiratory Antiviral Treatment Product
Table 72. Teva Pharmaceutical Industries Ltd. Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 73. Teva Pharmaceutical Industries Ltd. Recent Development
Table 74. Sun Pharmaceutical Industries Ltd. Company Details
Table 75. Sun Pharmaceutical Industries Ltd. Business Overview
Table 76. Sun Pharmaceutical Industries Ltd. Respiratory Antiviral Treatment Product
Table 77. Sun Pharmaceutical Industries Ltd. Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 78. Sun Pharmaceutical Industries Ltd. Recent Development
Table 79. GlaxoSmithKline plc Company Details
Table 80. GlaxoSmithKline plc Business Overview
Table 81. GlaxoSmithKline plc Respiratory Antiviral Treatment Product
Table 82. GlaxoSmithKline plc Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 83. GlaxoSmithKline plc Recent Development
Table 84. Mylan Inc. Company Details
Table 85. Mylan Inc. Business Overview
Table 86. Mylan Inc. Respiratory Antiviral Treatment Product
Table 87. Mylan Inc. Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 88. Mylan Inc. Recent Development
Table 89. Merck & Co., Inc. Company Details
Table 90. Merck & Co., Inc. Business Overview
Table 91. Merck & Co., Inc. Respiratory Antiviral Treatment Product
Table 92. Merck & Co., Inc. Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 93. Merck & Co., Inc. Recent Development
Table 94. AstraZeneca plc. Company Details
Table 95. AstraZeneca plc. Business Overview
Table 96. AstraZeneca plc. Respiratory Antiviral Treatment Product
Table 97. AstraZeneca plc. Revenue in Respiratory Antiviral Treatment Business (2020-2025) & (US$ Million)
Table 98. AstraZeneca plc. Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
Table 102. Authors List of This Report
List of Figures
Figure 1. Respiratory Antiviral Treatment Picture
Figure 2. Global Respiratory Antiviral Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Respiratory Antiviral Treatment Market Share by Type: 2024 VS 2031
Figure 4. Influenza Features
Figure 5. Bronchiolitis Features
Figure 6. Pneumonia Features
Figure 7. Upper Respiratory Tract Infections (URTIs) Features
Figure 8. Others Features
Figure 9. Global Respiratory Antiviral Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Respiratory Antiviral Treatment Market Share by Application: 2024 VS 2031
Figure 11. Hospital Pharmacies Case Studies
Figure 12. Retail Pharmacies Case Studies
Figure 13. Online Pharmacies Case Studies
Figure 14. Respiratory Antiviral Treatment Report Years Considered
Figure 15. Global Respiratory Antiviral Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Respiratory Antiviral Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Respiratory Antiviral Treatment Market Share by Region: 2024 VS 2031
Figure 18. Global Respiratory Antiviral Treatment Market Share by Players in 2024
Figure 19. Global Top Respiratory Antiviral Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Antiviral Treatment as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Respiratory Antiviral Treatment Revenue in 2024
Figure 21. North America Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Respiratory Antiviral Treatment Market Share by Country (2020-2031)
Figure 23. United States Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Respiratory Antiviral Treatment Market Share by Country (2020-2031)
Figure 27. Germany Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Respiratory Antiviral Treatment Market Share by Region (2020-2031)
Figure 35. China Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Respiratory Antiviral Treatment Market Share by Country (2020-2031)
Figure 43. Mexico Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Respiratory Antiviral Treatment Market Share by Country (2020-2031)
Figure 47. Turkey Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Respiratory Antiviral Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 51. Novartis AG Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 52. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 53. Pfizer, Inc. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 54. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 55. Sun Pharmaceutical Industries Ltd. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 56. GlaxoSmithKline plc Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 57. Mylan Inc. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 58. Merck & Co., Inc. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 59. AstraZeneca plc. Revenue Growth Rate in Respiratory Antiviral Treatment Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Household Embroidery Machines Market Research Report 2025
Jul 18, 25
Global Residential Electric Underfloor Heating Market Research Report 2025
Jul 18, 25
Global Commercial Electric Underfloor Heating Market Research Report 2025
Jul 18, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232